Consensus report from the 6th International forum for liver MRI using gadoxetic acid (Q38219801)

31 August 2017

title

Consensus report from the 6th International forum for liver MRI using gadoxetic acid (English)

1 reference

31 August 2017

1

1 reference

31 August 2017

8

1 reference

Markus Peck-Radosavljevic

31 August 2017

7

object named as

Markus Peck-Radosavljevic

0 references

Jeong Min Lee

5

object named as

Jeong Min Lee

1 reference

31 August 2017

10

Michiie Sakamoto

1 reference

31 August 2017

Hero K Hussain

2

1 reference

31 August 2017

Eduard Jonas

3

1 reference

31 August 2017

Masayuki Kanematsu

4

1 reference

31 August 2017

Elmar M Merkle

6

1 reference

31 August 2017

Jens Ricke

9

1 reference

31 August 2017

publication date

8 November 2013

1 reference

Journal of Magnetic Resonance Imaging

31 August 2017

published in

1 reference

31 August 2017

volume

40

1 reference

31 August 2017

issue

3

1 reference

31 August 2017

page(s)

516-529

1 reference

Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

CT- and MRI-based volumetry of resected liver specimen: comparison to intraoperative volume and weight measurements and calculation of conversion factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

"State of the art" in liver resection and living donor liver transplantation: a worldwide survey of 100 liver centers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

How much remnant is enough in liver resection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Assessment of liver function for safe hepatic resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Quantitative assessment of hepatic function and its relevance to the liver surgeon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Total and segmental liver volume variations: implications for liver surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Assessment of future remnant liver function using hepatobiliary scintigraphy in patients undergoing major liver resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Liver function testing with nuclear medicine techniques is coming of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Can imaging modalities diagnose and stage hepatic fibrosis and cirrhosis accurately?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

MR relaxometry of the liver: significant elevation of T1 relaxation time in patients with liver cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Segmental liver hyperintensity in malignant biliary obstruction on diffusion weighted MRI: associated MRI findings and relationship with serum alanine aminotransferase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Primovist, Eovist: what to expect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

The value of gadoxetate disodium-enhanced MR imaging for predicting posthepatectomy liver failure after major hepatic resection: a preliminary study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Estimation of liver function using T1 mapping on Gd-EOB-DTPA-enhanced magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Quantitative evaluation of liver function with use of gadoxetate disodium-enhanced MR imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Assessment of liver function in primary biliary cirrhosis using Gd-EOB-DTPA-enhanced liver MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Combined quantification of liver perfusion and function with dynamic gadoxetic acid-enhanced MR imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Feasibility of randomized controlled trials in liver surgery using surgery-related mortality or morbidity as endpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Contrast agents for MR imaging of the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Appearances of colorectal hepatic metastases at diffusion-weighted MRI compared with histopathology: initial observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Diffusion weighted imaging in the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Detection of liver metastases using gadoxetic-enhanced dynamic and 10- and 20-minute delayed phase MR imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatoce

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Improved characterization of focal liver lesions with liver-specific gadoxetic acid disodium-enhanced magnetic resonance imaging: a multicenter phase 3 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Diagnostic efficacy of gadoxetic acid-enhanced MRI for the detection and characterisation of liver metastases: comparison with multidetector-row CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Combining diffusion-weighted MRI with Gd-EOB-DTPA-enhanced MRI improves the detection of colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

High resolution navigated three-dimensional T₁-weighted hepatobiliary MRI using gadoxetic acid optimized for 1.5 Tesla.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Liver MRI in the hepatocyte phase with gadolinium-EOB-DTPA: does increasing the flip angle improve conspicuity and detection rate of hypointense lesions?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the Detection of hepatocellular carcinoma in patients with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Gadolinium ethoxybenzyl diethylenetriamine pentaacetic Acid-enhanced magnetic resonance imaging findings of borderline lesions at high risk for progression to hypervascular classic hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Double-dose gadoxetic Acid-enhanced magnetic resonance imaging in patients with chronic liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Relationship between liver function and liver signal intensity in hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging--correlation with expression of sinusoidal and canalicular transporters and bile accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Cirrhotic Rat Liver: Reference to Transporter Activity and Morphologic Changes in Bile Canaliculi—Gadoxetic Acid–enhanced MR Imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Hyperintense lesions on gadoxetate disodium-enhanced hepatobiliary phase imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Relationship between signal intensity on hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced MR imaging and prognosis of borderline lesions of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Contrast-enhanced magnetic resonance imaging of 102 nodules in cirrhosis: correlation with histological findings on explanted livers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Early hepatocellular carcinoma as an entity with a high rate of surgical cure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Outcome of hypovascular hepatic nodules revealing no gadoxetic acid uptake in patients with chronic liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Hypovascular hepatic nodule showing hypointensity in the hepatobiliary phase of gadoxetic acid-enhanced MRI in patients with chronic liver disease: prediction of malignant transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Management of hepatocellular carcinoma: An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Diagnostic efficacy of gadoxetic acid-enhanced MRI in the detection of hepatocellular carcinomas: comparison with gadopentetate dimeglumine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Assessment of Gd-EOB-DTPA-enhanced MRI for HCC and dysplastic nodules and comparison of detection sensitivity versus MDCT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

21 January 2018

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Gadoxetic acid-enhanced MRI versus multiphase multidetector row computed tomography for evaluating the viable tumor of hepatocellular carcinomas treated with image-guided tumor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using gadoxetic acid-enhanced MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Typical and atypical imaging findings of intrahepatic cholangiocarcinoma using gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Hepatocellular carcinoma in patients with chronic liver disease: a comparison of gadoxetic acid-enhanced MRI and multiphasic MDCT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

"Pseudo washout" sign in high-flow hepatic hemangioma on gadoxetic acid contrast-enhanced MRI mimicking hypervascular tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Which is the best MRI marker of malignancy for atypical cirrhotic nodules: hypointensity in hepatobiliary phase alone or combined with other features? Classification after Gd-EOB-DTPA administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Gadoxetate disodium-enhanced MR imaging: differentiation between early-enhancing non-tumorous lesions and hypervascular hepatocellular carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Small (≤ 2 cm) hepatocellular carcinoma in patients with chronic liver disease: comparison of gadoxetic acid-enhanced 3.0 T MRI and multiphasic 64-multirow detector CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Detection of small hepatocellular carcinoma: can gadoxetic acid-enhanced magnetic resonance imaging replace combining gadopentetate dimeglumine-enhanced and superparamagnetic iron oxide-enhanced magnetic resonance imaging?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Comparison of gadoxetic acid-enhanced MRI and superparamagnetic iron oxide-enhanced MRI for the detection of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Comparison between areas with Gd-EOB-DTPA uptake and without in hepatocellular carcinomas on Gd-EOB-DTPA-enhanced hepatobiliary-phase MR imaging: pathological correlation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Hepatocellular carcinoma in patients with cirrhosis: qualitative comparison of gadobenate dimeglumine-enhanced MR imaging and multiphasic 64-section CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Diagnostic sensitivity of imaging modalities for hepatocellular carcinoma smaller than 2 cm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI versus gadobenate dimeglumine (Gd-BOPTA)-enhanced MRI for preoperatively detecting hepatocellular carcinoma: an initial experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Gadoxetic acid-enhanced MRI findings of early hepatocellular carcinoma as defined by new histologic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Estimation of liver function using T2* mapping on gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid enhanced magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Assessment of hepatic extraction fraction and input relative blood flow using dynamic hepatocyte-specific contrast-enhanced MRI

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤ 2 cm) HCC in cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Magnetic resonance elastography as a predictor of insufficient liver enhancement on gadoxetic acid-enhanced hepatocyte-phase magnetic resonance imaging in patients with type C hepatitis and Child-Pugh class A disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Imaging Characteristics of Hepatocellular Carcinoma Using the Hepatobiliary Contrast Agent Gd-EOB-DTPA

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

Hypervascular hepatocellular carcinomas: detection with gadoxetate disodium-enhanced MR imaging and multiphasic multidetector CT

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24419

21 January 2018

Identifiers

DOI

10.1002/JMRI.24419

1 reference

31 August 2017

1 reference